Sage Therapeutics (SAGE) Competitors $8.28 -0.38 (-4.39%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$8.28 +0.01 (+0.06%) As of 03/28/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAGE vs. TARS, HRMY, TVTX, JANX, IRON, AGIO, APGE, MESO, VERA, and GLPGShould you be buying Sage Therapeutics stock or one of its competitors? The main competitors of Sage Therapeutics include Tarsus Pharmaceuticals (TARS), Harmony Biosciences (HRMY), Travere Therapeutics (TVTX), Janux Therapeutics (JANX), Disc Medicine (IRON), Agios Pharmaceuticals (AGIO), Apogee Therapeutics (APGE), Mesoblast (MESO), Vera Therapeutics (VERA), and Galapagos (GLPG). These companies are all part of the "pharmaceutical products" industry. Sage Therapeutics vs. Tarsus Pharmaceuticals Harmony Biosciences Travere Therapeutics Janux Therapeutics Disc Medicine Agios Pharmaceuticals Apogee Therapeutics Mesoblast Vera Therapeutics Galapagos Tarsus Pharmaceuticals (NASDAQ:TARS) and Sage Therapeutics (NASDAQ:SAGE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, community ranking and risk. Which has more risk & volatility, TARS or SAGE? Tarsus Pharmaceuticals has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Does the MarketBeat Community favor TARS or SAGE? Sage Therapeutics received 581 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. However, 68.42% of users gave Tarsus Pharmaceuticals an outperform vote while only 65.12% of users gave Sage Therapeutics an outperform vote. CompanyUnderperformOutperformTarsus PharmaceuticalsOutperform Votes5268.42% Underperform Votes2431.58% Sage TherapeuticsOutperform Votes63365.12% Underperform Votes33934.88% Do insiders and institutionals have more ownership in TARS or SAGE? 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.2% of Sage Therapeutics shares are owned by institutional investors. 8.3% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 5.5% of Sage Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is TARS or SAGE more profitable? Tarsus Pharmaceuticals has a net margin of -103.64% compared to Sage Therapeutics' net margin of -971.50%. Tarsus Pharmaceuticals' return on equity of -55.86% beat Sage Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tarsus Pharmaceuticals-103.64% -55.86% -39.28% Sage Therapeutics -971.50%-68.18%-60.84% Which has stronger valuation and earnings, TARS or SAGE? Tarsus Pharmaceuticals has higher revenue and earnings than Sage Therapeutics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTarsus Pharmaceuticals$182.95M10.85-$135.89M-$3.10-16.69Sage Therapeutics$41.24M12.34-$400.67M-$6.59-1.26 Do analysts rate TARS or SAGE? Tarsus Pharmaceuticals presently has a consensus target price of $63.67, suggesting a potential upside of 23.05%. Sage Therapeutics has a consensus target price of $8.81, suggesting a potential upside of 6.43%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Tarsus Pharmaceuticals is more favorable than Sage Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Sage Therapeutics 2 Sell rating(s) 15 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer TARS or SAGE? In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Sage Therapeutics. MarketBeat recorded 6 mentions for Tarsus Pharmaceuticals and 4 mentions for Sage Therapeutics. Sage Therapeutics' average media sentiment score of 0.93 beat Tarsus Pharmaceuticals' score of 0.65 indicating that Sage Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Sage Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTarsus Pharmaceuticals beats Sage Therapeutics on 14 of the 19 factors compared between the two stocks. Remove Ads Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAGE vs. The Competition Export to ExcelMetricSage TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$509.06M$6.90B$5.64B$7.84BDividend YieldN/A2.74%4.59%4.01%P/E Ratio-1.267.2023.4718.71Price / Sales12.34218.61388.1890.76Price / CashN/A65.6738.1734.64Price / Book1.106.386.894.23Net Income-$400.67M$142.34M$3.20B$247.47M7 Day Performance2.22%-5.15%-3.06%-2.29%1 Month Performance13.42%-7.55%1.51%-5.81%1 Year Performance-55.82%-11.06%9.35%-0.94% Sage Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAGESage Therapeutics2.9797 of 5 stars$8.28-4.4%$8.81+6.4%-55.8%$509.06M$41.24M-1.26690TARSTarsus Pharmaceuticals1.8596 of 5 stars$52.36+4.8%$63.67+21.6%+42.3%$2.01B$182.95M-13.7450Insider TradeHRMYHarmony Biosciences4.4474 of 5 stars$34.24-2.9%$53.33+55.8%-1.2%$1.96B$714.73M16.23200TVTXTravere Therapeutics2.7671 of 5 stars$21.29+3.7%$30.62+43.8%+155.3%$1.89B$233.18M-5.19460News CoveragePositive NewsJANXJanux Therapeutics2.66 of 5 stars$31.74+6.0%$92.44+191.3%-22.7%$1.88B$10.59M-27.1330Positive NewsIRONDisc Medicine3.1531 of 5 stars$53.70+2.8%$93.80+74.7%-15.9%$1.86BN/A-13.4930Insider TradePositive NewsAGIOAgios Pharmaceuticals4.3328 of 5 stars$32.31+3.2%$56.57+75.1%+3.6%$1.85B$36.50M2.85390Short Interest ↓Positive NewsAPGEApogee Therapeutics2.3846 of 5 stars$40.84+2.5%$92.17+125.7%-40.2%$1.84BN/A-16.8891Positive NewsMESOMesoblast1.7966 of 5 stars$14.39+3.2%$18.00+25.1%+141.7%$1.83B$5.67M0.0080VERAVera Therapeutics3.0988 of 5 stars$27.15+0.3%$64.67+138.2%-38.2%$1.73BN/A-10.4040GLPGGalapagos0.5984 of 5 stars$25.95+0.5%$26.75+3.1%-20.9%$1.71B$275.65M0.001,123News Coverage Remove Ads Related Companies and Tools Related Companies Tarsus Pharmaceuticals Competitors Harmony Biosciences Competitors Travere Therapeutics Competitors Janux Therapeutics Competitors Disc Medicine Competitors Agios Pharmaceuticals Competitors Apogee Therapeutics Competitors Mesoblast Competitors Vera Therapeutics Competitors Galapagos Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SAGE) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
